Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer
Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.
Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.
In the study, 196 patients were randomized to receive the veliparib combination regimen or placebo plus chemotherapy. Veliparib plus chemotherapy demonstrated improvements for both progression-free survival and overall survival compared with chemotherapy alone, which was carboplatin and paclitaxel, Diéras says. Additionally, the overall response rate with veliparib was found to be statistically significant.
Regarding safety, veliparib was associated with no meaningful adverse events, she adds. The most common treatment-emergent adverse events in either arm were neutropenia, thrombocytopenia, and nausea.
